Improving clinical benefit for prostate cancer patients through the combination of androgen deprivation and immunotherapy.

ABSTRACT: Androgen-deprivation therapy (ADT) induces prostate cancer immunogenic modulation (IM) by reducing human tumor cell expression of anti-apoptotic genes thus facilitating increased sensitivity to immune-mediated lysis. Through its stimulation of IM, ADT has been shown to synergize with active immunotherapy thereby significantly improving overall survival in a mouse model of prostate cancer.

SUBMITTER: Kwilas AR 

PROVIDER: S-EPMC4485836 | biostudies-literature | 2015 Jun

REPOSITORIES: biostudies-literature